Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Rapport sur les actions

Capitalisation boursière : US$845.6m

Adaptive Biotechnologies Bilan de santé

Santé financière contrôle des critères 5/6

Adaptive Biotechnologies possède un total de capitaux propres de $223.6M et une dette totale de $132.7M, ce qui porte son ratio d'endettement à 59.4%. Son actif total et son passif total sont $558.5M et de $334.9M.

Informations clés

59.4%

Ratio d'endettement

US$132.70m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$243.33m
Fonds propresUS$223.57m
Total du passifUS$334.93m
Total des actifsUS$558.51m

Mises à jour récentes de la santé financière

Recent updates

Adaptive Biotechnologies: Making Some Progress

Nov 26

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ADPT ( $308.3M ) dépassent ses passifs à court terme ( $87.6M ).

Passif à long terme: Les actifs à court terme de ADPT ( $308.3M ) dépassent ses passifs à long terme ( $247.3M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: ADPT dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de ADPT est passé de 0% à 59.4% au cours des 5 dernières années.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ADPT dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ADPT dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 29.6 % chaque année


Découvrir des entreprises saines